High prevalence of liver fibrosis associated with HIV infection: A study in rural Rakai, Uganda

Antiviral Therapy

Volumn 16, Issue 3, 2011, Pages 405-411

  Stabinski, Lara ^a   Reynolds, Steven J ^a,b   Ocama, Ponsiano ^c   Laeyendecker, Oliver ^a   Ndyanabo, Anthony ^d   Kiggundu, Valerian ^d   Boaz, Iga ^a,d   Gray, Ron H ^d,e   Wawer, Maria ^d,e   Thio, Chloe ^b   Thomas, David L ^b   Quinn, Thomas C ^a,b   Kirk, Gregory D ^e  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAKERERE UNIVERSITY   (Uganda)

^d RAKAI HEALTH SCIENCES PROGRAM   (Uganda)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ELASTOGRAPHY; FEMALE; FISHING; HEPATITIS B; HEPATOBILIARY PARAMETERS; HERBAL MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORBIDITY; MORTALITY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; RURAL AREA; SEX DIFFERENCE; UGANDA;

ADULT; ELASTICITY IMAGING TECHNIQUES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIVER CIRRHOSIS; MALE; PREVALENCE; RISK FACTORS; RURAL POPULATION; UGANDA;

EID: 79959434560     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1783     Document Type: Article

References (32)

1. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42:799-805. (Pubitemid 40693195)
2. The D:A:D Study. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
3. Thio CL, Seaberg EC, Skolasky R, Jr., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926. (Pubitemid 35472132)
4. Lacombe K, Boyd A, Desvarieux M, et al. Impact of chronic hepatitis C and/or D on liver fibrosis severity in patients co-infected with HIV and hepatitis B virus. AIDS 2007; 21:2546-2549. (Pubitemid 350145192)
5. Crum-Cianflone NF. Nonalcoholic fatty liver disease: an increasingly common cause of liver disease among HIV-infected persons? AIDS Read 2007; 17:513-518. (Pubitemid 47599388)
6. Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007; 21:1301-1308. (Pubitemid 46883484)
7. Weidle PJ, Moore D, Mermin J, et al. Liver enzymes improve over twenty-four months of first-line nonnucleoside reverse transcriptase inhibitor-based therapy in rural Uganda. AIDS Patient Care STDS 2008; 22:787-795.
8. Wawer MJ, Gray RH, Sewankambo NK, et al. A randomized, community trial of intensive sexually transmitted disease control for AIDS prevention, Rakai, Uganda. AIDS 1998; 12:1211-1225. (Pubitemid 28302424)
9. Kirk GD, Astemborski J, Mehta SH, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009; 48:963-972.
10. Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 2003; 3:21.
11. Martin-Carbonero L, de Ledinghen V, Moreno A, et al. Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. J Viral Hepat 2009; 16:790-795.
12. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306-1310. (Pubitemid 29168769)
13. Ocama P, Nambooze S, Opio CK, Shiels MS, Wabinga HR, Kirk GD. Trends in the incidence of primary liver cancer in Central Uganda, 1960-1980 and 1991-2005. Br J Cancer 2009; 100:799-802.
14. Lupsor M, Badea R, Stefanescu H, et al. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J Gastrointestin Liver Dis 2010; 19:53-60.
15. de Lédinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41:175-179.
16. Castellares C, Barreiro P, Martin-Carbonero L, et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat 2008; 15:165-172. (Pubitemid 351143738)
17. Kirk GD, Ocama P, Stabinski L, et al. High prevalence of HCV seroreactivity without detectable viremia in rural Ugandans. 13th International Symposium on Viral Hepatitis and Liver Disease. 20-24 March 2009, Washington, DC, USA. Abstract 346.
18. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004; 18:2039-2045. (Pubitemid 39463357)
19. Mohsen AH, Easterbrook PJ, Taylor C, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003; 52:1035-1040. (Pubitemid 36765298)
20. Bruno R, Galastri S, Sacchi P, et al. gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut 2010; 59:513-520.
21. Balagopal A, Philp FH, Astemborski J, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008; 135:226-233. (Pubitemid 351899010)
22. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713. (Pubitemid 37468321)
23. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virusand hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-287. (Pubitemid 32702341)
24. WHO. WHO global status report on alcohol 2004. (Accessed 23 March 2011.) Available from http://www.who.int/substance-abuse/publications/global-status- report-2004-overview.pdf
25. WHO. WHO policy perspectives on medicines - Traditional medicine - growing needs and potential. (Accessed 28 March 2011.) Available from http://wholibdoc.who.int/hq/2002/WHO-EDM-2002.4.pdf
26. Tsang VC, Wilkins PP. Immunodiagnosis of schistosomiasis. Immunol Invest 1997; 26:175-188. (Pubitemid 27066917)
27. Nwokolo C, Okonkwo P. Aflatoxin load of common food in savanna and forest regions of Nigeria. Trans R Soc Trop Med Hyg 1978; 72:329-332. (Pubitemid 8389141)
28. Jonsyn FE, Lahai GP. Mycotoxic flora and mycotoxins in smoke-dried fish from Sierra Leone. Nahrung 1992; 36:485-489.
29. Kuniholm MH, Lesi OA, Mendy M, et al. Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa. Environ Health Perspect 2008; 116:1553-1557.
30. Senba M, Nakamura T, Itakura H. Relationships among iron accumulation, cirrhosis, and hepatitis B virus infection in Bantu siderosis. Ann Soc Belg Med Trop 1989; 69:77-78.
31. De Cock KM, Awadh S, Raja RS, et al. Chronic splenomegaly in Nairobi, Kenya. II. Portal hypertension. Trans R Soc Trop Med Hyg 1987; 81:107-110.
32. Bonnard P, Sombie R, Lescure FX, et al. Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso. Am J Trop Med Hyg 2010; 82:454-458.